COVID-19 and Payor Strategies for Non-Medical Switching
Adam Friedman, MD, FAAD discusses how payors accelerated non-medical switching during COVID-19 and how healthcare providers can respond to new challenges.
Read More
How to Discourage Non-Medical Switching
A key opinion leader emphasizes the importance of discouraging non-medical switching by communicating with patients and partnering with industry researchers.
Impact of Non-Medical Switching on the Patient
Adam Friedman, MD, FAAD provides insight into how non-medical therapeutic switching affects clinical, economic, and psychological outcomes for patients.
Non-Medical Switching of Biosimilars and Generics
An expert in dermatology discusses the potential impact of non-medical switching to biosimilars and generic formulations on safety and efficacy profiles.
Why and How Non-Medical Therapeutic Switching Occurs
Adam Friedman, MD, FAAD defines non-medical therapeutic switching and discusses common tactics payors use to pressure practitioners and patients to switch.